Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
153
Views
9
Downloads
Abstract
This study embarked on a comprehensive examination of various clinical and immunological facets of patients diagnosed with systemic lupus erythematosus (SLE), employing a detailed analysis of multiple data sets to pinpoint distinctive patterns and correlations in patient profiles, disease manifestations, and antibody prevalence. A meticulous analysis of 102 patients was undertaken, comprising a demographic profiling (age, gender, occupation, marital status) and an extensive examination of symptom prevalence, mucocutaneous manifestations, neuropsychiatric manifestations, renal involvement, and cardiovascular manifestations. The SLE Disease Activity Index (SLEDAI) and calprotectin levels were also evaluated to ascertain their relationship with disease severity. The majority of the participants were females (96.08%), predominantly aged between 20 and 39 years. Common symptoms were fatigue (66.67%) and alopecia (75.49%). A significant portion of the patients had an SLEDAI score between 4 and 12 (48.03%), with a mean score of 10.32±8.34. Notably, a direct correlation between SLEDAI score and serum calprotectin levels was observed (p<0.001, r = 0.84). Moreover, elevated calprotectin levels were significantly associated with increased 24‐hour urinary protein levels (p<0.001, r = 0.75). This study underlines the complex clinical presentations of SLE patients, accentuating the significant prevalence of particular symptoms and immunological markers. The findings also elucidate a significant correlation between disease activity, as indicated by the SLEDAI score, and serum calprotectin levels, offering a potential avenue for future research in monitoring disease progression and facilitating early intervention strategies.
How to cite this article:
Himanish Goswami, Diganta Das, Bikashita Mahanta, Sanjeeb Kakati and Priyanka Priyadarshini Baishya. Serum Calprotectin in Systemic Lupus Erythematosus and its Relation to Disease Activity.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.11.65.72
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.11.65.72